On Apr. 13, 2021, a clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, was launched.

The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), was sponsored and funded by the National Institute of Allergy and Infectious Diseases.